Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Long-Term Investments (2020 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Long-Term Investments for 6 consecutive years, with $702.3 million as the latest value for Q3 2025.

  • Quarterly Long-Term Investments fell 1.42% to $702.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $702.3 million through Sep 2025, down 1.42% year-over-year, with the annual reading at $702.3 million for FY2025, 1.42% down from the prior year.
  • Long-Term Investments hit $702.3 million in Q3 2025 for Universe Pharmaceuticals, down from $712.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $712.5 million in Q3 2024 to a low of $702890.0 in Q3 2022.
  • Historically, Long-Term Investments has averaged $432.6 million across 5 years, with a median of $702.3 million in 2023.
  • Biggest five-year swings in Long-Term Investments: tumbled 98.44% in 2022 and later soared 99822.61% in 2023.
  • Year by year, Long-Term Investments stood at $45.1 million in 2021, then crashed by 98.44% to $702890.0 in 2022, then skyrocketed by 99822.61% to $702.3 million in 2023, then grew by 1.44% to $712.5 million in 2024, then dropped by 1.42% to $702.3 million in 2025.
  • Business Quant data shows Long-Term Investments for UPC at $702.3 million in Q3 2025, $712.5 million in Q3 2024, and $702.3 million in Q3 2023.